Anticoagulant Reversal Drugs Market Scope And Analysis

Report Code : TIPRE00004954
Category : Life Sciences

No. of Pages : 150

Buy Now

Anticoagulant Reversal Drugs Market Scope and Analysis by 2031

Buy Now

Anticoagulant Reversal Drugs Market Report Scope

Report Attribute	Details
Market size in 2023	US$ 1306.40 Million
Market Size by 2031	US$ 2,442.87 Million
Global CAGR (2023 - 2031)	10.08%
Historical Data	2021-2022
Forecast period	2024-2031
Segments Covered	By Product Prothrombin Complex Concentrates Vitamin K Protamine Tranexamic Acid Idarucizumab AndeXXa By Product Prothrombin Complex Concentrates Vitamin K Protamine Tranexamic Acid Idarucizumab AndeXXa
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Sanofi Johnson Johnson Glaxosmithkline Bausch Health Takeda Pharmaceuticals Lexicon Pharmaceuticals Inc Takeda Pharmaceuticals AbbVie Inc

Anticoagulant Reversal Drugs Market News and Recent Developments

The anticoagulant reversal drugs market is evaluated by gathering qualitative and quantitative data from primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for speech and language disorders and strategies:

AstraZeneca Pharma India Ltd. announced that it received approval from the Central Drugs Standard Control Organisation (CDSCO) in India to import and market Andexanet Alfa. This treatment is effective in addressing life-threatening or refractory bleeding that comes with the use of Factor Xa (FXa) inhibitors. (Source: AstraZeneca Pharma, Press Release, 2024)
Octapharma USA announced the approval of Balfaxar from the US Food and Drug Administration (FDA). Balfaxar is a non-activated four-factor prothrombin complex concentrate (4F-PCC) containing vitamin K-dependent factors: Factor II (prothrombin), Factor VII, Factor IX, and Factor X, and antithrombotic Proteins C and S. It can be used to urgently reverse acquired coagulation factor deficiency induced by vitamin K antagonist (VKA) therapy in adult patients who require urgent surgery or invasive procedures. Balfaxar helps restore blood coagulation by replenishing the levels of deficient clotting factors due to warfarin therapy. (Source: Octapharma USA, Inc, Press Release, 2023)

Anticoagulant Reversal Drugs Market Report Coverage and Deliverables

The “Anticoagulant Reversal Drugs Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
Market dynamics such as drivers, restraints, and key opportunities
Key future trends
Detailed PEST/Porter’s Five Forces and SWOT analysis
Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
Detailed company profiles